[October 18, 2017] |
|
Insulet and Dexcom Partner to Offer Choices for Animas Users
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company) the leader
in tubeless
insulin pump technology with its Omnipod® Insulin
Management System (Omnipod System), is partnering with DexCom, Inc.
(Dexcom) to provide the Omnipod System and a $200 gift card from Dexcom
which can be used towards the purchase of a Dexcom G5® Mobile
CGM (Continuous Glucose Monitoring) for qualified Animas®
insulin pump users.1 The program provides Animas users with
an easy way to experience freedom from tubing and the ability to dose
insulin without finger pricks.
This press release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20171018006532/en/
The Omnipod
Welcome Program includes a no cost trial of the Omnipod System, a
free box of Pods (10 count), and the opportunity to receive a $200 gift
card for completing a Dexcom patient survey to upgrade to the Dexcom G5
CGM.2 Animas pump switchers who have recently taken advantage
of the existing Omnipod Welcome Program may still take advantage of this
Dexcom offer as long as they are not an already-existing customer of
Dexcom.
"We created this program to provide a way for Animas users to experience
the freedom of the Omnipod System with the peace of mind of Dexcom's
market-leading CGM," said Bret Christensen, Chief Commercial Officer of
Insulet. "Managing diabetes is a very personal decision and we strongly
support an individual's right to choice when it comes to their diabetes
management. This partnership is just one example of our commitment to
support people with diabetes today and over the long term."
"Dexcom is excited to partner with Insulet to offer this special
promotion," said Rick Doubleday, Chief Commercial Officer of Dexcom.
"This provides Animas users the opportunity to upgrade to our
best-sellig Dexcom G5 Mobile CGM and have easier access to the only
tubeless pump system in the U.S."
As the number one pediatric preferred pump3, which is also
quickly gaining adoption with adults, the Omnipod System uses a
tubeless, waterproof patch-pump technology that offers users significant
quality of life benefits. The differentiated design provides up to 72
hours of nonstop, discreet insulin delivery, and more choice for site
selection. It eliminates the burden associated with multiple daily
injections and the complexity associated with traditional tubed pumps.
When used with the Dexcom G5 Mobile CGM, users will benefit from fewer
finger sticks, fewer components to carry and wear, and access to pump
and blood glucose data from their smart-phone with Insulet provided
Glooko.
For full offer details and to get started, Animas patients should call
the Insulet Customer Care Team at 1-888-643-8763. Offer terms and
conditions are subject to change. Please click
here for full promotion details.
1The Omnipod Insulin Management System and the Dexcom G5 CGM
are not integrated, are sold separately, and function independently.
2These promotions are two independent offerings and therefore
an individual may take advantage of either one separately or both. You
may be required to submit a form directly to Dexcom.
3dQ&A Q3 2016 Patient Panel Survey. Share of parents of
children with type 1 diabetes on an insulin pump who had chosen the
Omnipod® was higher than for other pumps. Statistical
significance of results calculated at the 95% confidence level.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD) is an innovative medical device
company dedicated to making the lives of people with diabetes
easier. Insulet seeks to expand the use of insulin pump therapy with its
Omnipod Insulin Management System among people with insulin-dependent
diabetes. The Omnipod System is a revolutionary and easy-to-use tubeless
insulin pump that provides up to three days of non-stop insulin
delivery, without the need to see or handle a needle. Insulet's Delivery
Systems business partners with global pharmaceutical and biotechnology
companies to adapt the Omnipod technology platform for the delivery of
subcutaneous drugs across multiple therapeutic areas. Founded in
2000, Insulet Corporation is based in Billerica, Massachusetts. For more
information, please visit: http://www.myomnipod.com.
Forward-Looking Statement:
This press release may contain forward-looking statements
concerning Insulet's expectations, anticipations, intentions, beliefs or
strategies regarding the future. These forward-looking statements are
based on its current expectations and beliefs concerning future
developments and their potential effects on Insulet. There can be no
assurance that future developments affecting Insulet will be those that
it has anticipated. These forward-looking statements involve a number of
risks, uncertainties (some of which are beyond its control) or other
assumptions that may cause actual results or performance to be
materially different from those expressed or implied by these
forward-looking statements, and other risks and uncertainties described
in its Annual Report on Form 10-K, which was filed with the Securities
and Exchange Commission on February 28, 2017 in the section entitled
"Risk Factors," and in its other filings from time to time with
the Securities and Exchange Commission. Should one or more of these
risks or uncertainties materialize, or should any of its assumptions
prove incorrect, actual results may vary in material respects from those
projected in these forward-looking statements. Insulet undertakes no
obligation to publicly update or revise any forward-looking statements.
© 2017 Insulet Corporation and Omnipod are trademarks or registered
trademarks of Insulet Corporation. All rights reserved. All other
trademarks are the property of their respective owners. The use of third
party trademarks does not constitute an endorsement or imply a
relationship or other affiliation.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171018006532/en/
[ Back To Mobile World Congress's Homepage ]
|